Pharmacokinetics of Topical Administration of Altrenogest in Mares and Implications for Human Health
Journal of Veterinary Pharmacology and Therapeutics · 2026-05 · 49 (3) · 274-281
DOI: 10.1111/jvp.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 26.02.2026. Verfasst von Jaymie Loy und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia. Hauptthemen laut MEDLINE: Horses, Trenbolone Acetate. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agrifutures Australia.
Abstract (Originalsprache)
Altrenogest is a synthetic progestogen widely used in equine reproductive management. Adverse effects to altrenogest have been reported in people with cutaneous exposure reported as the highest exposure pathway. Despite these reports, there has been no quantitative research to determine the capacity for altrenogest to be absorbed through skin. This study aimed to determine if cutaneous application of oral altrenogest results in systemic absorption in mares and to evaluate the influence of application site. A randomized, two‐period, two‐treatment crossover study was undertaken in eight mares. Mares received a topical application of oral altrenogest (0.044 mg/kg) onto clipped skin on either the neck or back for five consecutive days, with blood sampling immediately before and 1 h after each treatment. Following the final dose, blood samples were taken at 0.08, 0.16, 0.3, 0.5, 0.66, 0.83, 1, 1.5, 2, 4, 6, 8, 12, 24 and 48 h. After a 3‐week washout period mares underwent treatment on the alternative site, sampling at the same intervals. Plasma samples were analysed for altrenogest using LC–MS/MS and pharmacokinetic variables were estimated using noncompartmental analysis. Altrenogest was detectable in plasma following application at both sites. Peak plasma concentrations (C max ) were significantly higher following neck application (1.7 ± 0.7 ng/mL) compared to the back (0.6 ± 0.3 ng/mL; p = 0.002). Concentrations remained quantifiable throughout the 48‐h post‐treatment period. As altrenogest is absorbed through equine skin of varying thickness, there is a need for cautious use and handling, especially given that human skin is thinner than equine skin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
- Forensic and Toxicology Laboratory, NSW Heath Pathology, Sydney, Australia.
- Australian Racing Forensic Laboratory, Racing NSW, Sydney, Australia.
- Racing Analytical Services Limited, Flemington, Victoria, Australia.
ORCID-Profile: Jaymie Loy
Förderung
- Agrifutures Australia
Zitieren
APA
Loy, J., Sornalingam, K., Cawley, A., Scrivener, C., Keledjian, J., & Noble, G. K. (2026). Pharmacokinetics of Topical Administration of Altrenogest in Mares and Implications for Human Health. Journal of Veterinary Pharmacology and Therapeutics, 49(3), 274-281. https://doi.org/10.1111/jvp.70040
Vancouver
Loy J, Sornalingam K, Cawley A, Scrivener C, Keledjian J, Noble GK. Pharmacokinetics of Topical Administration of Altrenogest in Mares and Implications for Human Health. Journal of Veterinary Pharmacology and Therapeutics. 2026;49(3):274-281. doi:10.1111/jvp.70040
BibTeX
@article{Loy2026,
author = {Loy, Jaymie and Sornalingam, Kireesan and Cawley, Adam and Scrivener, Colin and Keledjian, John and Noble, Glenys K},
title = {Pharmacokinetics of Topical Administration of Altrenogest in Mares and Implications for Human Health},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2026},
volume = {49},
number = {3},
pages = {274--281},
doi = {10.1111/jvp.70040}
}
EUVIMED